The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Opko Health Inc. (drugs and diagnostics) has acquired privately held point-of-care testing company Claros Diagnostics Inc. Opko paid $10mm in cash and issued $20mm of its equity (4.5mm common shares at $4.45 apiece; market average); it could also hand over up to $19mm in shares as earn-outs for achieved milestones. (Oct.)
Claros, formed in 2004, developed a microfluidics-based quantitative blood test system using technology from Harvard University. The immunoassay platform...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
